Down-regulation of anti-inflammatory TIPE2 may aggravate adenoidal hypertrophy in children

Area of Science:

• Immunology
• Pediatrics
• Molecular Biology

Background:

• Adenoidal hypertrophy (AH) is a common pediatric condition with symptoms like nasal congestion and sleep apnea.
• Immune responses are implicated in AH pathogenesis, with elevated inflammatory markers like TNF-α and IL-6 observed.
• Tumor necrosis factor-alpha (TNF-α)-induced protein-8 like-2 (TIPE2) is a newly identified negative regulator of inflammatory pathways.

Purpose of the Study:

• To investigate the role of TIPE2 in pediatric adenoidal hypertrophy.
• To determine the correlation between TIPE2 expression levels and AH severity.
• To explore the potential of TIPE2 in modulating inflammatory pathways in AH.

Main Methods:

• Quantification of TNF-α and IL-6 levels in adenoid tissues from AH patients and controls.
• Assessment of TIPE2 expression in adenoid tissues.
• In vitro experiments involving TIPE2 overexpression in primary human monocytes from AH patients.

Main Results:

• Elevated TNF-α and IL-6 levels were found in AH tissues, correlating positively with AH severity.
• TIPE2 expression was significantly decreased in AH tissues, correlating negatively with AH severity.
• TIPE2 overexpression in monocytes inhibited nuclear factor-κB (NF-κB) activation and reduced TNF-α and IL-6 expression.

Conclusions:

• Reduced TIPE2 expression is associated with increased inflammation and severity in pediatric adenoidal hypertrophy.
• TIPE2 may play a protective role in AH by suppressing the NF-κB signaling pathway.
• TIPE2 warrants further investigation as a potential therapeutic target for adenoidal hypertrophy.